Skip to main content

Table 4 Tumor characteristics at diagnosis according to pathological complete response

From: Mammographic density is a potential predictive marker of pathological response after neoadjuvant chemotherapy in breast cancer

  pCRaNon-pCR
Number of patients 57245
Estrogen receptor statuspositive18 (31.6)165 (67.3)
negative38 (66.7)72 (29.4)
missing1 (1.8)8 (3.3)
Progesterone receptor statuspositive12 (21.1)128 (52.2)
negative44 (77.2)109 (44.5)
missing1 (1.8)8 (3.3)
HER2 statuspositive35 (61.4)60 (24.5)
negative20 (35.1)171 (69.8)
missing2 (3.5)14 (5.7)
Ki67> 20% (high)44 (77.2)161 (65.7)
<=20% (low)3 (5.3)36 (14.7)
missing10 (17.5)48 (19.6)
Axillary lymph nodepositive FNAb41 (71.9)156 (63.7)
negative FNA3 (5.3)19 (7.8)
inconclusive FNA 5 (2.0)
no FNA13 (22.8)64 (26.1)
missing 1 (0.4)
Tumor size at diagnosis (mm)cmedian (IQR)28 (20–35)35 (25–46)
  1. apathological complete response
  2. bfine needle aspiration
  3. cMeasured in mammograms or in ultrasound images. When both methods were conclusive an average measure was used